Published: November 29, 2018
We are pleased to announce that van Biema Value Partners and Chuck Royce have selected Caravan Capital, a $10-$50M Emerging Markets Hedge Fund, as the final winner of the van Biema Value Partners Ex-US Small-Cap Challenge, a special initiative designed to identify talented, under-the-rader fund m...
Published: July 09, 2018
In the wake of Canada's landmark legalization of recreational cannabis, we asked three Cap Intro funds invested in the space to offer insights on their investment strategy as well as the competitive landscape, technological innovations, and political headwinds shaping the legal cannabis industry.
Published: July 07, 2016
In the aftermath of Brexit, many investors have forgotten about the continuing shakeup in pharmaceuticals. The S&P Pharmaceuticals Select Industry Index has fallen by 28% in the last year, with prominent hedge funds losing particularly big on much-hyped Valeant (VRX:CN). According to SumZero cont...
Published: July 03, 2012
Our analysis indicates there is over 50% upside to the share price from current levels (with some not-too-unreasonable DCF scenarios indicating as much as 100% upside), although it would likely take several years to close this gap to intrinsic value.
Published: April 26, 2012
The market views Sanofi as a large European pharma company with a patent cliff. I believe the stock will be revalued due to the change in business mix, geographical mix, and the lack of patent exposure past 2012. Sanofi has valuable franchises in Generics, Consumer Products, Animal Health, Vaccin...
Published: September 11, 2012
AstraZeneca (NYSE: AZN)
Current Price: $45.00
Target Price: $62.00
Source: Hedge Fund. Boston, MA.
Quick Thesis
2011 has seen an increased focus on cash generation and returns within the sector, in anticipation of the 2012 trough combined with the continued decline in global markets sentim...